References

0

01: The GTN "Surveillance for Adverse Events Following Immunizations" training course has been held at: University of Cape Town in South Africa; National Pharmacovigilance Centre in Tunisia; Epidemiological Unit, Ministry of Health in Sri Lanka; and, Tarassevich Institute in Russia. For more information, see https://www.who.int/immunization_standards/vaccine_quality/gtn_aefi/en/.
02: Immunization. In: World Health Organization [website]. Geneva: World Health Organization; 2021 (https://www.who.int/news-room/facts-in-pictures/detail/immunization, accessed 10 April 2021).
03: The Global Vaccine Action Plan 2011–2020: Review and lessons learned. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/bitstream/handle/10665/329097/WHO-IVB-19.07-eng.pdf, accessed 10 April 2021).
04: Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low- and middle-income countries, 2011–20. Health Aff (Millwood). 2016;35(2):199–207.
05: World Health Organization Immunization, Vaccines and Biologics (WHO/IVB) database. Database includes 193 WHO Member States. Data as of July 2009.
06: Immunization Agenda 2030: A Global Strategy To Leave No One Behind. In: World Health Organization [website]. Geneva: World Health Organization; 2020 (https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind, accessed 10 April 2021).
07: Chen RT et al. "The Vaccine Adverse Event Reporting System (VAERS)," Vaccine, 1994: 12(6):542–550.
08: Wilson, CB, Marcuse, EK. "Vaccine safety – vaccine benefits: science and the public's perception," Nature Reviews Immunology, 2001: 1:160–165.
09: World Health Organization (WHO). Available at: https://www.who.int/biologicals/vaccines/smallpox/en/ (Accessed 2 December 2009).

1

10: United Nations Children Fund (UNICEF). Available at: http://www.unicef.org (Accessed 2 December 2009).
100: https://www.who.int/immunization/diseases/MNTE_initiative/en/
100: https://www.who.int/immunization/diseases/MNTE_initiative/en/
101: World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017; 92(19):241–268.
102: World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017;92(19):241–268.
103: Centers for Disease Control and Prevention (CDC). Manual for the Surveillance of Vaccine-Preventable Diseases – Chapter 16: Tetanus, Atlanta (2017).
104: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Clinical Safety assessment (E2a-e). Available on: https://www.ich.org.
105: Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Geneva: CIOMS; 2012 (https://cioms.ch/publications/product/definitions-and-applications-of-terms-for-vaccine-pharmacovigilance/, accessed 6 Mai 2021).
106: Immunization stress-related response. A manual for program managers and health professionals to prevent, identify and respond to stress- related responses following immunization. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/978-92-4-151594-8, accessed 6 Mai 2021).
11: Milstien, JB. "Regulation of vaccines: strengthening the science base," Journal Public Health Policy, 2004: 25(2):173–189.
12: Baylor NW, Midthun K. "Regulation and testing of vaccines," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.
13: Duclos P, Bentsi-Enchill AD, Pfeifer D. "Vaccine safety and adverse events: lessons learnt," In: Kaufmann SHE and Lamert PH. The Grand Challenge for the Future, Basel, Switzerland: 2005: 209–229.
14: Offit PA, David RL, Gust D. "Vaccine safety," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.
15: Malaria Vaccine Initiative, PATH. Fact Sheet: Clinical trials: Steps in malaria vaccine development, Seattle, Washington.
16: US Centers for Disease Control and Prevention (CDC). "Intussusception among recipients of rotavirus vaccine – United States, 1998–1999", Morbidity and Mortality Weekly Report, 1999: 48:577–581.
17: World Health Organization (WHO). Acute intussusception in infants and children: Incidence, clinical presentation and management: A global perspective, WHO/V&B/02.19, Geneva: WHO, 2002.
18: Ruiz-Palacios G, Pérez-Schael I, Velázquez F, et al. "Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis," New England Journal of Medicine, 2006: 354(1):11–22.
19: Vesikari T, Matson D, Dennehy P, et al. "Safety and efficacy of a pentavalent human-bovine (wc3) reassortant rotavirus vaccine," New England Journal of Medicine, 2006: 354(1):23–33.

2

20: Chen RT, Glasser J, Rhodes P et al. "Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States," Pediatrics, 1997: 99(6):765–773.
21: US Centers for Disease Control and Prevention. Website (Clinical Immunization Safety Assessment Network section) http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/ (Accessed 23 February 2010).
22: US Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices, February 21–22, 2007, Record of the Proceedings, Atlanta, Georgia: 2007.
23: US Centers for Disease Control and Prevention (CDC). "Prevention of rotavirus gastroenteritis among infants and children; recommendations of the Advisory Committee on Immunization Practices", Morbidity and Mortality Weekly Report, 2006: 55(RR-12).
24: Duclos P. "A global perspective on vaccine safety," Vaccine, 2004: 22:2059–2063.
25: European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine, EMEA/32706/2007: London, 19 January 2007.
26: Infant mortality and births from 2008 Immunization summary, WHO/UNICEF (The 2010 edition).
27: Uppsala Monitoring Centre. Available at: www.who-umc.org (Accessed 24 February 2010).
28: World Health Organization (WHO). "BCG vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2018; 93(8):73–96.
29: World Health Organization (WHO). "Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries", Weekly Epidemiological Record, Geneva: 2016; 91(12):145–168.

3

30: World Health Organization (WHO). "Pertussis vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2015;90(35):433–460.
31: World Health Organization (WHO). "Measles vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2017; 92(17):205–228.
32: World Health Organization (WHO). Aide mémoire: To ensure the efficiency and safety of mass immunization campaigns with injectable vaccines, WHO/V&B/04.07, Geneva: WHO, 2007.
33: World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, WHO/IVB/04.06, Geneva: WHO, 2004.
34: Black S, Eskola J, Siegrist C et al. "Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines," Lancet, Published Online October 21, 2009. DOI:10.1016/S0140- 6736(09)61877–8.
35: World Health Organization (WHO). "Causality assessment of adverse events following immunization", Weekly Epidemiological Record, Geneva: WHO, 2001: 76(12):85–89.
36: World Health Organization (WHO). Aide Mémoire: Adverse Events Following Immunization (AEFI): Causality Assessment, WHO/IVB, Geneva: 2005.
37: World Health Organization Western Pacific Regional Office (WHO/WPRO), PATH. Third Biregional Meeting on Control of Japanese Encephalitis, Manila: WHO, 2007.
38: World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety: Safety of Japanese encephalitis vaccination in India", Weekly Epidemiological Record, Geneva: WHO, 2007: 82(3):23–24.
39: Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS", Expert Review Vaccines, 2009:8(6) 705–716.

4

40: Brighton Collaboration: https://brightoncollaboration.us.
41: World Health Organization (WHO). Available at: https://www.who.int/immunization_standards/vaccine_quality/gtn_index/en/ (Accessed 18 March 2010).
42: https://www.who-umc.org/global-pharmacovigilance/who-programme-for-international-drug-monitoring (Accessed 17 June 2021)
43: The Global Advisory Committee on Vaccine Safety (GACVS). Terms of reference. Geneva: World Health Organization; 2017 (https://www.who.int/publications/m/item/GACVS-TOR-170619, accessed 25 May 2021).
44: World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009", Weekly Epidemiological Record, Geneva: 2009: 84(40):330–332.
45: Vaccine Safety Net objective and general information. Geneva: World Health Organization; 2021 (https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/vaccine-safety-net)(Accessed 17 June 2021).
46: World Health Organization (WHO). The Importance of Pharmacovigilance: safety monitoring of medicinal products, Geneva: WHO, 2002.
47: WHO (2012). WHO vaccine reaction rates information sheets. https://www.who.int/initiatives/the-global-vaccine-safety-initiative/tools-and-methods/reaction-rates-information-sheets/.
48: Uppsala Monitoring Centre (UMC). Available at: www.who-umc.org (Accessed 18 November 2009).
49: Council for International Organizations of Medical Sciences/World Health Organization (CIOMS/WHO) Working Group on Vaccine Pharmacovigilance. Vaccine Pharmacovigilance Definition. Available at: www.cioms.ch (Accessed 10 February 2010).

5

50: Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS," Expert Review Vaccines, 2009: 8(6),705–716.
51: Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M and the VAERS Working Group. "Intussusception Among Recipients of Rotavirus Vaccine: Reports to the Vaccine Adverse Event Reporting System" Pediatrics, 2001: 107;e97 DOI:10.1542/peds.107.6.e97.
52: Robert Pless, Public Health Agency of Canada. (Personal communication January 2010).
53: World Health Organization (WHO). Available at: https://www.who.int/immunization_standards/national_regulatory_authorities/strengthening/en/ (Accessed 1 March 2009).
54: Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998–2005: inevitable community outrage or a failure of risk communication? Vaccine 24, 3912–3928 (2006).
55: World Health Organizaton Global Training Network. "Similarities and differences between vaccines and medicines," In: WHO Global Training Network: Adverse events following immunization (AEFI), Geneva: WHO, 2009.
56: World Health Organization (WHO). "Module 3: The cold chain" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.
57: World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.
58: World Health Organization (WHO). "Module 6: Holding an immunization session" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.
59: Gold R. Your Child's Best Shot: A parent's guide to vaccination 3rd edition, Canadian Paediatric Society, Canada, 2006.

6

60: Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical Safety Information on Drugs – Report of CIOMS Working Group III, Geneva: WHO, 1995.
61: World Health Organization (WHO). "Rotavirus vaccines: an update" Weekly Epidemiological Record, Geneva: 2009:84(51–52):533–538.
62: World Health Organization (WHO). "Yellow fever vaccine: WHO position paper" Weekly Epidemiological Record, Geneva: 2013;88(27):269–284.
63: World Health Organization (WHO). "Hepatitis B vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(27):369–392.
64: Asian Development Bank. Immunization Financing in Developing Countries and the International Vaccine Market: Trends and Issues, Manila: Asian Development Bank, 2001.
65: World Health Organization (WHO). "WHO position paper on Haemophilus influenzae type b conjugate vaccines", Weekly Epidemiological Record, Geneva: 2013;88(39):413–428.
66: World Health Organization (WHO). "Pneumococcal conjugate vaccine for childhood immunization – WHO position paper", Weekly Epidemiological Record, Geneva: 2019;94(8):85–104.
67: Meningitis vaccine project. Available at: www.meningvax.org (Accessed 1 January 2010).
68: World Health Organization (WHO). "Tetanus vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(6):53–76.
69: World Health Organization (WHO). "Diphtheria vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(31):417–436.

7

70: Adapted from Martin Friede.
71: Brief overview of anaphylaxis as AEFI and practical guidance on its identification, case management and response in a primary care setting. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/anaphylaxis-guidance, accessed 16 June 2021).
72: World Health Organization (WHO). "Revised BCG vaccination guidelines for infants at risk for HIV infection", Weekly Epidemiological Record, Geneva: 2007:82(21):193–196.
73: World Health Organization (WHO). "Influenza Vaccines WHO Position Paper", Weekly Epidemiological Record, No. 33, 19 August 2005.
74: World Health Organization (WHO). Website (Vaccine-preventable diseases section). Available at: https://www.who.int/immunization/diseases/MNTE_initiative/en/ (Accessed 19 May 2010).
75: World Health Organization (WHO). Website (Maternal and Neonatal Tetanus (MNT) elimination). Available at: https://www.who.int/immunization/diseases/MNTE_initiative/en/ (Accessed January 2012)
76: D. Baxter. (2007). Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 57 (8): 552–556. doi: 10.1093/occmed/kqm11.
77: World Health Organization (WHO). Website (Information related to influenza immunization). Available at: https://www.who.int/influenza/vaccines/SAGE_information/en/ (Accessed 25 May 2012).
78: Definition and Application of Terms for Vaccine Pharmacovigilance (2012).
79: WHO WER 2007; 82:17–24 and WER 2007; 82:181–96.

8

80: Siegrist CA, Lewis EM, Eskola J, Evans S, Black S. "Human Papilloma Virus Immunization in Adolescent and Young Adults: A Cohort Study to Illustrate What Events Might be Mistaken for Adverse Reactions." The Pediatric Infectious Disease Journal. Volume 26, Number 11, November 2007.
81: Expanded Programme on Immunization (EPI): https://www.who.int/immunization/programmes_systems/supply_chain/benefits_of_immunization/en/
82: WHO Programme for International Drug Monitoring (PIDM): https://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/
83: Uppsala Monitoring Center (UMC): https://www.who-umc.org
84: Global Advisory Committee on Vaccine Safety (GACVS): https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/
85: Brighton Collaboration: https://brightoncollaboration.us.
86: Standardized case definitions: https://brightoncollaboration.us/category/pubs-tools/case-definitions/
87: Information for health professionals: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/health-professionals-info
88: Global Learning Opportunities for Vaccine Quality:
https://www.who.int/immunization_standards/vaccine_quality/gtn_index/en/
89: WHO: Good information practices for vaccine safety web sites:
https://www.who.int/vaccine_safety/initiative/communication/network/approved_vaccine_safety_website/en/

9

90: More about the History of Anti-vaccination Movements: College of Physicians of Philadelphia: The history of vaccines: https://www.historyofvaccines.org/content/articles/history-anti-vaccination-movements
91: Haut Conseil de la Santé Publique (HCSP). Vaccinations des personnes immunodéprimées ou aspléniques (2012).
92: The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine, 2007; 25(31):5671—5674. https://pubmed.ncbi.nlm.nih.gov/17400339/
93: Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007; 25(31):5771—5792. https://pubmed.ncbi.nlm.nih.gov/17570566/
94: Adverse Effects of Vaccines: Evidence and Causality:
https://www.nap.edu/catalog/13164/adverse-effects-of-vaccines-evidence-and-causality
95: Vaccine Safety Net: https://www.who.int/vaccine_safety/initiative/communication/network/vaccine_safety_websites/en/
96: UMC Pharmacovigilance Training Course: https://www.who-umc.org/education-training/education-training/international-pharmacovigilance-training-course/
97: Global Vaccine Safety Blueprint Strategy: https://vaccine-safety-training.org/tl_files/vs/pdf/WHO_IVB_12.07_eng.pdf
98: Guillard-Maure C, Elango V, Black S, Perez-Vilar S, Castro JL, Bravo-Alcantara P et al. Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative. Vaccine. 2018;36(3):355–362.
99: World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017;92(19):241–268